Jul 2026
Pan-Cancer Multi-Omics and Structure-Guided Drug Discovery Identify TUBG1 as a Clinically and Immunologically Relevant Target
This pan-cancer study supports TUBG1 as a clinically and immunogenomically relevant candidate and nominates computationally prioritized inhibitors for experimental validation.
Muhammad Alaa Eldeen, E. Fayad, Soha Y Alkhaldi et al.
· Journal of Computational Bio... · 0 citations